|(A;A)||2||aspirin use may increase colorectal cancer risk a bit|
|(A;T)||2||aspirin use may increase colorectal cancer risk a bit|
|(T;T)||2||common/normal; aspirin use reduces colorectal cancer risk a bit|
In a long-term study of ~17,000 individuals and aspirin or NSAID use, the few (4%) with either an (A;T) or (A;A) genotype were almost twice as likely to be diagnosed with colorectal cancer compared with (T;T) individuals among those taking anti-inflammatory drugs (prevalence, 28% vs 38%; (T;T) odds ratio 0.66 when taking aspirin/NSAID, CI: 0.61-0.70, p = 7.7 × 10e−33); prevalence, 35% vs 29%; (A;T) and (A;A) odds ratio 1.89 when taking aspirin/NSAID, CI: 1.27-2.81, p = .002). 10.1001/jama.2015.1815
If this data is robust and all other factors are equal, this indicates that most people will lower their colorectal cancer risk by taking aspirin or NSAIDs, since most people have rs2965667(T;T) genotypes. However, the few people who are rs2965667(A;T) or are rs2965667(A;A) should not take aspirin or NSAIDs since doing so may actually raise their colorectal risk.
This same study reached somewhat similar conclusions about two other SNPs, rs10505806 and rs16973225.10.1001/jama.2015.1815[PMID 25781442] Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants